Intellia Therapeutics NTLA 深 沪
等待开盘 10-28 09:30:00 美东时间
14.79
-10.810
-42.23%
华盛通- 最 高16.7605
- 今 开13.73
- 成交量 5253.06万股
- 最 低 13.21
- 昨 收 25.60
- 总市值 15.83亿
- 52周最高 28.25
- 市盈率 静 --
- 换手率 49.09%
- 52周最低 5.90
- 委 比 -89.53%
- 总股本 1.07亿
- 历史最高 202.73
- 量 比 10.65
- 振 幅 13.87%
- 历史最低 5.90
- 每 手 1
- 风险率 4.23%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 买入！Fermi、Neptune获多家大行首予评级；伯克希尔哈撒韦罕见地获得“卖出”评级；摩根大通上调苹果目标价升至290美元
今日重点评级关注：Guggenheim：上调Neumora Therapeutics评级至"买入"，目标价14美元；韦德布什：上调Fate Therapeutics评级至"跑赢大市"，目标价从5美元升至7美元
今天 10:08
nex-z三期临床试验出现严重不良事件 Intellia(NTLA.US)股价暴跌超40%
Intellia Therapeutics公司（NTLA.US）在暂停两项nexiguran ziclumeran（简称nex-z）三期临床试验的给药后，其股价于周一交易中一度暴跌47.6%，收跌42.23%。
今天 08:25
Intellia’s NTLA-2002: A Promising Long-Term Study Update
Intellia Therapeutics Inc (($NTLA)) announced an update on their ongoing clinic...
今天 01:58
Why Is Intellia Therapeutics (NTLA) Down 45% Today?
Intellia Therapeutics stock dove on Monday alongside an update to a Phase 3 cli...
10-27 20:58
Intellia plummets following severe adverse event in phase 3 nex-z trial
Intellia Therapeutics (NASDAQ:NTLA) shares are down ~45% in premarket trading Monday after pausing dosing in two phase 3 trials for nexiguran ziclumeran (nex-z). The pause is due to a report of a pati...
10-27 20:32
快讯 | 美股基因编辑概念股盘前下挫，NTLA一度暴跌超60%
基因编辑公司 $Intellia Therapeutics (NTLA.US)$ 盘前一度暴跌超60%，消息面上，该公司宣布暂停其针对转甲状腺素蛋白淀粉样伴心肌...
10-27 20:17
Intellia Halts CRISPR Drug Trials for Amyloidosis to Investigate Serious Liver Event
Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that the company has temporarily paused patient
10-27 19:34
Intellia Therapeutics Provides Update on MAGNITUDE Clinical Trials of Nexiguran Ziclumeran (nex-z)
Intellia Therapeutics has temporarily paused patient dosing and screening for its MAGNITUDE and MAGNITUDE-2 Phase 3 trials of nex-z due to a serious adverse event in a patient, including Grade 4 liver transaminases and increased bilirubin. The company is consulting with experts, developing risk mitigation strategies, and engaging with regulatory authorities. Over 650 patients with transthyretin amyloidosis with cardiomyopathy (ATTR-CM) and 47 wit...
10-27 11:30
深度｜诺奖背后生物技术公司力量迅速崛起，科学家创业有何秘诀？
在做科研的时候，一定是挑专业领域里最难的问题去攻克，而在创办企业的时候，应该要挑最容易的那部分去做，这样才最有可能将科研成果转化为实际的经济收益。 诺贝...
10-12 14:06
美联储降息再迎大消息，纳指生科创年内新高，纳指生物科技ETF(513290)强势收涨6.22%，连续16日获资金加仓，“吸金”近7300万元
隔夜（10月8日）美股收盘，美股三大指数涨跌不一，纳指涨1.12%，标普500指数涨0.58%，两者均创收盘新高，道指收平。纳斯达克生物科技指数收涨0.89%...
10-09 17:58
